Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The forecast has been revised upward based on first-half results in the Medical and NC businesses. In the Medical business, growth drivers including Rexulti, Lonsurf and VOYXACT progressed steadily, while the entry of generic competition for JINARC in the US and Abilify Maintena in Europe was delayed beyond initial expectations. In the NC business, the Healthier Life category performed strongly, and the foreign exchange assumptions were revised to reflect the yen's depreciation against the US dollar and euro.
| Item | Details |
|---|---|
| Net Sales | 2,520,000 Millions of yen → 2,725,000 Millions of yen（8.1%） |
| Operating profit | 360,000 Millions of yen → 469,000 Millions of yen（30.3%） |
| Profit attributable to owners of the parent | 269,000 Millions of yen → 360,000 Millions of yen（33.8%） |
| Net income per share | ¥504.94 → ¥675.47 |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Revenue: ¥2,468,892 million; business profit: ¥446,129 million; operating profit: ¥479,375 million; profit before tax: ¥468,037 million; profit for the year: ¥366,216 million; profit for the year attributable to owners of the parent: ¥363,150 million; basic earnings per share: ¥685.06 |
| Reason for the revision | The forecast has been revised upward based on first-half results in the Medical and NC businesses. In the Medical business, growth drivers including Rexulti, Lonsurf and VOYXACT progressed steadily, while the entry of generic competition for JINARC in the US and Abilify Maintena in Europe was delayed beyond initial expectations. In the NC business, the Healthier Life category performed strongly, and the foreign exchange assumptions were revised to reflect the yen's depreciation against the US dollar and euro. |
| Dividend forecast revision | The interim dividend has been increased from ¥70.00 to ¥100.00 per share, and the year-end dividend forecast has been increased from ¥70.00 to ¥100.00 per share. The full-year dividend forecast has been revised from ¥140.00 to ¥200.00 per share, an increase of ¥60 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The revisions reflect first-half results in the Medical and NC businesses, progress by the Medical business's growth drivers, delays in generic competition entering the US and European markets, strong performance in the Healthier Life category of the NC business, and a review of the foreign exchange assumptions in light of the yen's depreciation. The dividend revisions reflect better-than-expected second-quarter results, the upward revision to the full-year earnings forecast, and the company's progressive dividend policy.